Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome

Abstract

Metabolic syndrome (MetS) is associated with increased incidence of diabetes and cardiovascular disease (CVD). Prospective clinical trials with alpha-tocopherol (AT) have not yielded positive results. Because AT supplementation decreases circulating gamma-tocopherol (GT), we evaluated supplementation with GT (800 mg/day), AT (800 mg/day), the combination or placebo for 6 weeks alone AT and GT concentrations, biomarkers of oxidative stress, and inflammation in subjects with MetS (n=20/group). Plasma AT and GT levels increased following supplementation with AT alone or GT alone or in combination. AT supplementation significantly decreased GT levels. Urinary alpha- and gamma-CEHC, metabolites of the respective Ts, also increased correspondingly, i.e., alpha-CEHC with AT and gamma-CEHC with GT supplementation, compared to placebo. HsCRP levels significantly decreased in the combined AT+GT group. LPS-activated whole blood release of IL-1 and IL-6 did not change. There was a significant decrease in TNF with AT alone or in combination with GT. Plasma MDA/HNE and lipid peroxides were significantly decreased with AT, GT, or in combination. Nitrotyrosine levels were significantly decreased only with GT or GT+AT but not with AT compared to placebo. Thus, the combination of AT and GT supplementation appears to be superior to either supplementation alone on biomarkers of oxidative stress and inflammation and needs to be tested in prospective clinical trials to elucidate its utility in CVD prevention.

Figures

Fig. 1

Effect of AT, GT, and AT+GT supplementation on plasma AT and plasma GT Levels: Plasma AT and GT levels were measured at baseline and at Week 6 (postsupplementation) in the four groups as described under Subjects and methods. *P<0.001 compared to baseline and placebo. $P<0.01 compared to baseline and GT. #P<0.05 compared to GT alone.

Fig. 2

Effect of AT, GT, and AT+GT supplementation on plasma alpha and gamma CEHC levels: Plasma A-CEHC and G-CEHC levels were measured at baseline and at Week 6 (postsupplementation) in the four groups as described under Subjects and methods. *P<0.001 compared to baseline and placebo.

Fig. 3

Effect of AT, GT, and AT+GT supplementation on urinary alpha and gamma CEHC levels: Urine A-CEHC and G-CEHC levels were measured at baseline and at Week 6 (postsupplementation) in the four groups as described under Subjects and methods and standardized to creatinine. *P <0.001 compared to baseline and placebo; *aP<0.01 compared to AT.

Fig. 4

(a) Effect of AT, GT, and AT+GT supplementation on HsCRP Levels: HsCRP levels were measured at baseline and at Week 6 (postsupplementation) in the four groups as described under Subjects and methods. *P<0.001 compared to baseline and *aP<0.02 compared to placebo. (b) Effect of AT, GT, and AT+GT supplementation on urine nitrotyrosine levels: HsCRP levels were measured at baseline and at Week 6 (postsupplementation) in the four groups as described under Subjects and methods and standardized to creatinine. *aP<0.02 compared to baseline and placebo.